Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 85
Filtrar
1.
Cardiovasc Toxicol ; 19(3): 229-236, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30377924

RESUMEN

The abuse of new psychoactive substances (NPS) is an emerging social problem. Methoxetamine, one of the NPS, was designed as an alternative to ketamine and it was considered an NPS candidate owing to its high addictive potential. However, cardiotoxicity of the phencyclidine analogue, methoxetamine, has not been extensively evaluated. P21 protein (Cdc42/Rac)-activated kinase 1 (PAK-1) is associated with the drug-induced cardiotoxicity and hypertrophy of cardiomyocytes. In the present study, we investigated the effects of methoxetamine on rat cardiomyocytes and PAK-1. Methoxetamine (at 10 µM) reduced cell viability and PAK-1 mRNA levels in H9c2 cells. Methoxetamine treatment (100 µM) decreased the beating rate of primary cardiomyocytes. However, 100 µM methoxetamine-induced heart rate decline was less than 100 µM PCP- or ketamine-induced heart rate decline. Meanwhile, fingolimod hydrochloride (FTY720, 1 µM), a PAK-1 activator, increased cell viability and inhibited hypertrophy induced by methoxetamine in H9c2 cells. These results suggest that methoxetamine may have harmful effects on the cardiovascular system through the regulation of the expression and function of PAK-1.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Drogas Ilícitas/toxicidad , Miocitos Cardíacos/efectos de los fármacos , Quinasas p21 Activadas/metabolismo , Animales , Cardiotoxicidad , Tamaño de la Célula/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Canal de Potasio ERG1/efectos de los fármacos , Canal de Potasio ERG1/metabolismo , Frecuencia Cardíaca/efectos de los fármacos , Células Hep G2 , Humanos , Ratones Endogámicos ICR , Miocitos Cardíacos/enzimología , Miocitos Cardíacos/patología , Ratas , Transducción de Señal/efectos de los fármacos
2.
Bioorg Med Chem ; 27(1): 161-166, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-30503782

RESUMEN

Inspite of progress made for the discovery of novel antiepileptic drugs, epilepsy remains an unmet medical need. We synthesized nine trifluoromethylated enaminone derivatives and tested them for their anticonvulsant activity using maximal electroshock seizure (MES) test, subcutaneous pentylenetetrazole (scPTZ) test, and rotorod test for neurotoxicity. Among the compounds tested 3-(4-fluoro-3-(trifluomethyl)benzylamino)-5-(trifluoromethyl)cyclohex-2-enone (4f) showed ED50 of 23.47 mg/kg, when given orally to rats, 3-(4-chlorophenylamino)-5-(trifluoromethyl)cyclohex-2-enone (5a), which was previously reported by us but for which no quantitative data was available at the time, exhibited an ED50 of 62.39 mg/kg. Under the same conditions commercially available carbamazepine showed an ED50 of 28.20 mg/kg. There were no neurotoxicity observed upto a dose of 300 mg/kg for all the tested compounds. Compounds 4f and 5a represent good lead compounds for further development.


Asunto(s)
Anticonvulsivantes/farmacología , Bencilaminas/farmacología , Ciclohexanonas/farmacología , Ciclohexilaminas/farmacología , Hidrocarburos Fluorados/farmacología , Convulsiones/prevención & control , Animales , Anticonvulsivantes/síntesis química , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/toxicidad , Bencilaminas/síntesis química , Bencilaminas/farmacocinética , Bencilaminas/toxicidad , Simulación por Computador , Ciclohexanonas/síntesis química , Ciclohexanonas/farmacocinética , Ciclohexanonas/toxicidad , Ciclohexilaminas/síntesis química , Ciclohexilaminas/farmacocinética , Ciclohexilaminas/toxicidad , Diseño de Fármacos , Hidrocarburos Fluorados/síntesis química , Hidrocarburos Fluorados/farmacocinética , Hidrocarburos Fluorados/toxicidad , Masculino , Ratones , Estructura Molecular , Ratas , Relación Estructura-Actividad
3.
Am J Physiol Heart Circ Physiol ; 314(3): H659-H668, 2018 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-29127238

RESUMEN

Clinical studies have suggested that myocardial iron is a risk factor for left ventricular remodeling in patients after myocardial infarction. Ferroptosis has recently been reported as a mechanism of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well understood. Mechanistic target of rapamycin (mTOR) protects the heart against pathological stimuli such as ischemia. To define the role of cardiac mTOR on cell survival in iron-mediated cell death, we examined cardiomyocyte (CM) cell viability under excess iron and ferroptosis conditions. Adult mouse CMs were isolated from cardiac-specific mTOR transgenic mice, cardiac-specific mTOR knockout mice, or control mice. CMs were treated with ferric iron [Fe(III)]-citrate, erastin, a class 1 ferroptosis inducer, or Ras-selective lethal 3 (RSL3), a class 2 ferroptosis inducer. Live/dead cell viability assays revealed that Fe(III)-citrate, erastin, and RSL3 induced cell death. Cotreatment with ferrostatin-1, a ferroptosis inhibitor, inhibited cell death in all conditions. mTOR overexpression suppressed Fe(III)-citrate, erastin, and RSL3-induced cell death, whereas mTOR deletion exaggerated cell death in these conditions. 2',7'-Dichlorodihydrofluorescein diacetate measurement of reactive oxygen species (ROS) production showed that erastin-induced ROS production was significantly lower in mTOR transgenic versus control CMs. These findings suggest that ferroptosis is a significant type of cell death in CMs and that mTOR plays an important role in protecting CMs against excess iron and ferroptosis, at least in part, by regulating ROS production. Understanding the effects of mTOR in preventing iron-mediated cell death will provide a new therapy for patients with myocardial infarction. NEW & NOTEWORTHY Ferroptosis has recently been reported as a new form of iron-dependent nonapoptotic cell death. However, ferroptosis in the heart is not well characterized. Using cultured adult mouse cardiomyocytes, we demonstrated that the mechanistic target of rapamycin plays an important role in protecting cardiomyocytes against excess iron and ferroptosis.


Asunto(s)
Hierro/metabolismo , Daño por Reperfusión Miocárdica/prevención & control , Miocitos Cardíacos/enzimología , Serina-Treonina Quinasas TOR/metabolismo , Animales , Carbolinas/toxicidad , Muerte Celular , Supervivencia Celular , Células Cultivadas , Ciclohexilaminas/toxicidad , Compuestos Férricos/toxicidad , Masculino , Ratones Endogámicos C57BL , Ratones Transgénicos , Daño por Reperfusión Miocárdica/enzimología , Daño por Reperfusión Miocárdica/patología , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/patología , Fenilendiaminas/toxicidad , Piperazinas/toxicidad , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal , Serina-Treonina Quinasas TOR/genética
4.
Regul Toxicol Pharmacol ; 85: 25-32, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28159477

RESUMEN

In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation. The murine Local Lymph Node Assay (LLNA) and its modifications are widely used to fulfil the data requirement, as it is currently considered the first-choice method for in vivo testing to cover this endpoint. This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used. While the BrdU-ELISA modification of the LLNA using acetone/olive oil (AOO) as vehicle revealed expectable positive results. However, the concentration control analysis unexpectedly revealed an instability of MCDA in the vehicle AOO. Further studies on the reactivity showed MCDA to rapidly react with AOO under formation of various imine structures, which might have caused the positive LLNA result. The repetition of the LLNA using propylene glycol (PG) as vehicle did not confirm the positive results of the LLNA using AOO. Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.


Asunto(s)
Alérgenos , Ciclohexilaminas , Excipientes/química , Haptenos , Acetona/química , Alérgenos/química , Alérgenos/clasificación , Alérgenos/toxicidad , Animales , Ciclohexilaminas/química , Ciclohexilaminas/clasificación , Ciclohexilaminas/toxicidad , Dermatitis Alérgica por Contacto , Femenino , Haptenos/química , Haptenos/clasificación , Haptenos/toxicidad , Ensayo del Nódulo Linfático Local , Ratones Endogámicos CBA , Aceite de Oliva/química , Propilenglicol/química , Sensibilidad y Especificidad
5.
Int J Mol Sci ; 18(1)2017 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-28106785

RESUMEN

The novel synthetic psychoactive ketamine analog methoxetamine is reportedly being used for recreational purposes. As ketamine use can result in urinary dysfunction, we conducted the present study to investigate how methoxetamine affects the bladder. A cystometry investigation showed that female Sprague-Dawley rats experienced increased micturition frequency bladder dysfunction after receiving a daily intraperitoneal injection of 30 mg/kg methoxetamine or ketamine for periods of 4 or 12 weeks. Histologic examinations of rat bladder tissue revealed damaged urothelium barriers, as well as evidence of inflammatory cell infiltration and matrix deposition. The drug-treated rats showed significantly upregulated levels of pro-inflammatory cytokines such as IL-1ß, IL-6, CCL-2, CXCL-1, CXCL-10, NGF, and COX-2. In addition, interstitial fibrosis was confirmed by increased levels of collagen I, collagen III, fibronectin and TGF-ß. Besides direct toxic effect on human urothelial cells, methoxetaminealso induced the upregulation related cytokines. Our results indicate that long term methoxetamine treatment can induce bladder dysfunction and inflammation in rats. Methoxetamine was confirmed to produce direct toxic and pro-inflammatory effects on human urothelial cells. Methoxetamine-associated bladder impairment may be similar to ketamine-induced cystitis.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Inflamación/patología , Ketamina/análogos & derivados , Vejiga Urinaria/patología , Vejiga Urinaria/fisiopatología , Animales , Peso Corporal/efectos de los fármacos , Línea Celular , Quimiocinas/genética , Quimiocinas/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Células Epiteliales/patología , Epitelio/efectos de los fármacos , Epitelio/patología , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Mastocitos/efectos de los fármacos , Mastocitos/patología , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/patología , Ratas , Ratas Sprague-Dawley , Regulación hacia Arriba/efectos de los fármacos , Vejiga Urinaria/efectos de los fármacos , Micción/efectos de los fármacos , Urodinámica/efectos de los fármacos
6.
Drug Alcohol Rev ; 35(2): 212-7, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25867295

RESUMEN

INTRODUCTION AND AIMS: To assess the prevalence of use and subjective effect profile of methoxetamine among a group of polydrug users. DESIGN AND METHODS: Cross-sectional, anonymous, online survey of UK-based polydrug users was conducted. Prevalence of lifetime, last year and last month use, sourcing of the drugs, motivations for use, and subjective effect and risk profile compared with that of ketamine were measured. RESULTS: There were 7700 UK-based polydrug users, of whom 326 reported recent use of methoxetamine. Of the whole sample, 4.2% reported last 12 month use of methoxetamine compared with 24.5% for ketamine. The most common route of use was intranasal and the predominate effect described as psychedelic. Of the 15.5% of last year users of ketamine reporting last year use of methoxetamine, only 18.7% reported that they thought methoxetamine was less damaging to their kidneys or bladder than ketamine. Its broad effect profile, based on participants' first experience of use, was very similar to that of ketamine. Almost one-third of users reported that they did not intend to try the drug again. DISCUSSION AND CONCLUSIONS: Methoxetamine appears to have a broadly similar effect profile to that of ketamine. Only a minority of participants were motivated to use it because they believed it was less damaging to their kidneys or bladder than ketamine. The impact of the recent temporary banning order on availability and use of both methoxetamine and ketamine should be monitored carefully.


Asunto(s)
Ciclohexanonas/administración & dosificación , Ciclohexilaminas/administración & dosificación , Alucinógenos/administración & dosificación , Drogas Ilícitas , Trastornos Relacionados con Sustancias/epidemiología , Adulto , Estudios Transversales , Ciclohexanonas/farmacología , Ciclohexanonas/toxicidad , Ciclohexilaminas/farmacología , Ciclohexilaminas/toxicidad , Femenino , Alucinógenos/farmacología , Alucinógenos/toxicidad , Humanos , Drogas Ilícitas/farmacología , Drogas Ilícitas/toxicidad , Ketamina/administración & dosificación , Ketamina/farmacología , Ketamina/toxicidad , Masculino , Motivación , Prevalencia , Encuestas y Cuestionarios , Reino Unido/epidemiología , Adulto Joven
7.
Hum Psychopharmacol ; 30(4): 244-8, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26216557

RESUMEN

OBJECTIVE: The goal of this study is to provide an update on the data given on methoxetamine (MXE)-related fatalities that occurred in 2011-2013, presented at the Second International Conference on Novel Psychoactive Substances. METHODS: Fatalities involving MXE were extracted from the database of the National Programme on Substance Abuse Deaths, which receives information on drug-related deaths from Coroners in the UK and Islands (Isle of Man, Jersey, Guernsey) and other data suppliers. RESULTS: Eight cases, received by 3 September 2013, in which MXE was found at post-mortem and/or directly implicated in the death and/or mentioned in the Coroner's verdict are described. The median age at death was 27 years, with the majority of White ethnicity (6/8) and male (7/8). MXE was used together with other substances in 7/8 cases. MXE was found at post-mortem in all cases, directly implicated in the deaths of four and likely to have had an influence in two. CONCLUSIONS: More research needs to be conducted into its health effects and toxicity potential. Health care professionals should be made aware of the potential health harms of MXE, in order to develop early intervention measures and minimise the number of MXE-related poisonings and fatalities.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Drogas Ilícitas/toxicidad , Trastornos Relacionados con Sustancias/mortalidad , Adolescente , Adulto , Diagnóstico , Femenino , Humanos , Masculino , Estudios Retrospectivos , Reino Unido , Adulto Joven
9.
Mil Med ; 179(10): 1149-57, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25269134

RESUMEN

Recent years have seen the emergence and proliferation of "legal highs" or "designer drugs," compounds purposefully designed as legal alternatives to controlled substances of abuse. This article describes methoxetamine, a dissociative drug belonging to the arylcyclohexylamine class including phencyclidine and ketamine. Methoxetamine acts principally on the glutamatergic N-methyl-D-aspartate receptor and the serotonin receptor. It is sold as a white or off-white powder. Marketed as a "bladder friendly" alternative to ketamine, preliminary research suggests renal and cystic toxicity similar to ketamine. Methoxetamine is primarily ingested nasally, though also orally, intramuscularly, intravenously, and rectally. Users report dissociative features and, at higher doses, an "m-hole" experience akin to ketamine's "k-hole" described as extreme depersonalization and derealization. The 13 cases of acute methoxetamine toxicity described in the literature are summarized. The toxidrome consists of dissociation/delirium, sympathetic activation, and cerebellar symptoms. Methoxetamine is not detected in standard urine drug tests and there are no reliable laboratory findings. Management of acute methoxetamine toxicity is supportive, consisting of benzodiazepines, antiemetics, intravenous fluids, and respiratory support as indicated. Should methoxetamine conform to the observed 2-year lag of designer drugs migrating from Europe to the United States usage may increase in early 2014.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Drogas de Diseño/toxicidad , Drogas Ilícitas/toxicidad , Personal Militar , Humanos , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/terapia , Estados Unidos
10.
Toxicol Lett ; 230(3): 402-7, 2014 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-25128700

RESUMEN

Methoxetamine is one of the constantly growing group of novel psychoactive substances that has emerged in recent years. The compound belongs to the arylcyclohexylamine class, which is used for its recreational and psychedelic effects. Methoxetamine is a structural analogue of ketamine, with a much longer duration of action and intensity of effects, and has been extensively advertised as its 'legal' and 'bladder friendly' alternative. This review surveys the current state of knowledge regarding the metabolism, pharmacology, prevalence and pattern of methoxetamine use, and analytical methods of its detection. Consumption of methoxetamine bears a significant health risk and may even lead to fatal intoxication. A significant amount of research is still needed in order to fully quantify the short- and long-term effects of methoxetamine and its interaction with other drugs of abuse.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Alucinógenos/toxicidad , Drogas Ilícitas/toxicidad , Ciclohexanonas/administración & dosificación , Ciclohexanonas/química , Ciclohexilaminas/administración & dosificación , Ciclohexilaminas/química , Alucinógenos/administración & dosificación , Humanos , Drogas Ilícitas/efectos adversos , Ketamina/química , Ketamina/toxicidad , Trastornos Relacionados con Sustancias/etiología
11.
J Anal Toxicol ; 38(7): 410-5, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24904014

RESUMEN

Methoxetamine (MXE) is increasingly used and abused, as it is frequently presented as being safer than ketamine, and legal. Cases of only MXE consumption being associated with the occurrence of seizures are rarely reported. A single MXE intoxication case by inhalation is described concerning a 21-year-old man, not known to be epileptic, who was found collapsed in his bedroom, supposedly after an epileptic seizure. He was transferred to the Emergency Department of the Henri Mondor Hospital, Aurillac, France. He was conscious, but with a sinus bradycardia (48/min) and an ST-segment elevation on the electrocardiogram, and a slightly increased creatine kinase level (270 U/L) and hyponatremia (127 mmol/L). New seizure activity occurred during hospitalization, but the clinical course in the intensive care unit was favorable. Quantitation of MXE in serum and urine using gas chromatography coupled to mass spectrometry (GC-MS) was developed, as well as a liquid chromatography coupled to tandem mass spectrometry (LC-MS-MS) method for the determination of MXE in hair. Limits of detection and quantification were, respectively, 2 and 10 µg/L for the GC-MS method and both 0.5 pg/mg for the LC-MS-MS method. Concentrations of 30 and 408 µg/L were, respectively, measured in serum and urine. Concentrations of 135 and 145 pg/mg were detected in two 2.5 cm hair strands, consistent with one or several consumptions during the 2 ½ months prior to sampling. A sample of the powder consumed was available and also analyzed. This case illustrates the dangers of this drug, which justify its classification as a narcotic in France since August 2013.


Asunto(s)
Ciclohexanonas/análisis , Ciclohexanonas/toxicidad , Ciclohexilaminas/análisis , Ciclohexilaminas/toxicidad , Drogas Ilícitas/análisis , Drogas Ilícitas/toxicidad , Convulsiones/inducido químicamente , Detección de Abuso de Sustancias/métodos , Ciclohexanonas/sangre , Ciclohexanonas/orina , Ciclohexilaminas/sangre , Ciclohexilaminas/orina , Cromatografía de Gases y Espectrometría de Masas , Cabello/química , Humanos , Drogas Ilícitas/sangre , Drogas Ilícitas/orina , Exposición por Inhalación , Límite de Detección , Masculino , Reproducibilidad de los Resultados , Convulsiones/diagnóstico , Espectrometría de Masa por Ionización de Electrospray , Adulto Joven
12.
Clin Toxicol (Phila) ; 52(3): 176-80, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24580056

RESUMEN

UNLABELLED: CONTEXT.: Methoxetamine is a ketamine analogue that has recently emerged as a novel psychoactive substance. Chronic ketamine use is associated with significant bladder and renal toxicity. Methoxetamine has been marketed as "bladder friendly", but there is no data to be able to substantiate this claim. OBJECTIVE: To characterise the patterns of bladder and renal toxicity associated with 3 months of methoxetamine administration in an animal model. MATERIALS AND METHODS: Two-month-old Institute of Cancer Research mice were administered 30 mg/kg methoxetamine intraperitoneally (n = 5) or saline (n = 3 control) for 3 months. The animals were then sacrificed and histological examination, immuno-cytochemistry using polyclonal anti-CD4 antibodies and sirius-red staining for collagen were performed. RESULTS: The kidneys of methoxetamine-treated animals showed inflammatory cell infiltration, tubular cell necrosis and glomerular damage (1.9 ± 0.3% shrunken glomeruli in control, 9.8 ± 0.8% in methoxetamine-treated mice (p < 0.0001); 2.9 ± 0.3% tubular cell degeneration in control, 20.4 ± 1.1% in methoxetamine-treated mice (p < 0.0001)). There was a greater density of mononuclear cells in the bladder lamina propria and submucosa in methoxetamine-treated mice (43.0 ± 2.1 per 250 × 250 µm) than controls (7.1 ± 1.2 per 250 × 250 µm), p < 0.001. CD4-positive staining was seen in the bladder submucosa and lamina propria of all methoxetamine-treated mice and muscle-layer of two methoxetamine-treated mice; these changes were not seen in the control mice. There was an increase in sirius-red collagen in the bladder sub-mucosa and muscle-layer in the methoxetamine-treated mice compared with control mice. DISCUSSION: This study has shown that 3 months of daily 30 mg/kg intra-peritoneal methoxetamine results in significant bladder and renal toxicity in mice. Changes in the bladder included inflammatory changes with subsequent fibrosis and changes in the kidney were seen at both a tubular and glomerular level. These changes are similar to those seen in comparable animal models of chronic ketamine administration. Further work is required to determine the time course of the onset of these effects and whether the effects are reversible with methoxetamine cessation.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Riñón/efectos de los fármacos , Vejiga Urinaria/efectos de los fármacos , Animales , Riñón/patología , Masculino , Ratones , Ratones Endogámicos ICR , Factores de Tiempo , Vejiga Urinaria/patología
13.
Emerg Med J ; 31(1): 45-7, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23349353

RESUMEN

OBJECTIVE: To report the demographic and clinical characteristics of cases of methoxetamine toxicity reported to The National Poisons Information Service (NPIS) by healthcare professionals. To assess the pattern of enquiries from health professionals to the UK NPIS related to methoxetamine, including the period of the making of the UK first Temporary Class Drug Order (TCDO). METHODS: All telephone enquiries to and user sessions for TOXBASE, the NPIS on-line information resource, related to methoxetamine (and synonyms 'MXE', 'mket' and '2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone') were reviewed from 1 April 2010 to 1 August 2012. Data were compared for the 3 months before and after the TCDO. RESULTS: There were 47 telephone enquiries and 298 TOXBASE sessions regarding methoxetamine during the period of study. Comparing the 3 months before and after the TCDO, TOXBASE sessions for methoxetamine fell by 79% (from 151 to 32) and telephone enquiries by 80% (from 15 to 3). Clinical features reported by enquirers were consistent with case reports of analytically confirmed methoxetamine toxicity and typical toxidromes were of stimulant (36%), reduced consciousness (17%), dissociative (11%) and cerebellar (6.4%) types, but also particularly featured acute disturbances in mental heath (43%). CONCLUSIONS: Structured NPIS data may reveal trends in drugs of abuse use and toxicity when interpreted within their limitations. Since April 2012, there have been fewer enquiries to NPIS from clinicians, indicating reduced presentations with suspected methoxetamine toxicity to healthcare services. It is unclear if this is related to the TCDO made on 5 April 2012.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Ciclohexanonas/clasificación , Ciclohexilaminas/clasificación , Bases de Datos Factuales , Servicios de Información sobre Medicamentos , Trastornos Relacionados con Sustancias/epidemiología , Teléfono , Reino Unido
15.
Anal Bioanal Chem ; 405(19): 6307-21, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23774830

RESUMEN

Methoxetamine (MXE; 2-(3-methoxyphenyl)-2-(N-ethylamino)-cyclohexanone), a ketamine analog, is a new designer drug and synthesized for its longer lasting and favorable pharmacological effects over ketamine. The aims of the presented study were to identify the phases I and II metabolites of MXE in rat and human urine by GC-MS and LC-high-resolution (HR)-MS(n) and to evaluate their detectability by GC-MS and LC-MS(n) using authors' standard urine screening approaches (SUSAs). Furthermore, human cytochrome P450 (CYP) enzymes were identified to be involved in the initial metabolic steps of MXE in vitro, and respective enzyme kinetic studies using the metabolite formation and substrate depletion approach were conducted. Finally, human urine samples from forensic cases, where the ingestion of MXE was suspected, were analyzed. Eight metabolites were identified in rat and different human urines allowing postulation of the following metabolic pathways: N-deethylation, O-demethylation, hydroxylation, and combinations as well as glucuronidation or sulfation. The enzyme kinetic studies showed that the initial metabolic step in humans, the N-deethylation, was catalyzed by CYP2B6 and CYP3A4. Both SUSAs using GC-MS or LC-MS(n) allowed monitoring an MXE intake in urine.


Asunto(s)
Cromatografía Liquida/métodos , Ciclohexanonas/farmacocinética , Ciclohexilaminas/farmacocinética , Sistema Enzimático del Citocromo P-450/metabolismo , Drogas de Diseño/farmacocinética , Cromatografía de Gases y Espectrometría de Masas/métodos , Inactivación Metabólica , Ketamina/análogos & derivados , Animales , Ciclohexanonas/toxicidad , Ciclohexanonas/orina , Ciclohexilaminas/toxicidad , Ciclohexilaminas/orina , Sistema Enzimático del Citocromo P-450/química , Drogas de Diseño/toxicidad , Humanos , Cinética , Masculino , Ratas , Ratas Wistar
16.
Ther Drug Monit ; 34(4): 363-7, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22673201

RESUMEN

Since the turn of the 21st century, there has been an increase in the availability and use of novel psychoactive substances (also known as "legal highs") across Europe. Currently, there is limited information available on the potential acute toxicity (harms) associated with the use of these novel psychoactive substances. There are a number of potential data sources that can provide information on the acute toxicity associated with their use: (1) user reports on Internet discussion fora; (2) subpopulation level surveys of self-reported harms/unwanted effects (3) regional or national poisons information service accesses for support on presentations to healthcare facilities relating to acute toxicity; (4) case reports/series based on self-reported use or analytically confirmed use; and (5) human volunteer studies assessing potential acute toxicological effects. Each of these data sources has its own limitations, particularly those that are based on self-reported use because there are a number of European studies that show that there is inconsistency in the substance(s) in the "drug" that an individual uses. However, by using a multilayered approach of combining different sources, it is possible to reduce the overall impact of the limitations of any one individual data source. In this review article, we will combine information from these different data sources to describe the pattern of acute toxicity associated with 4 novel psychoactive substances: 1-benzylpiperazine, mephedrone (4-methylmethcathinone), synthetic cannabinoid receptor agonists, and methoxetamine.


Asunto(s)
Psicotrópicos/efectos adversos , Psicotrópicos/toxicidad , Animales , Antagonistas de Receptores de Cannabinoides/efectos adversos , Antagonistas de Receptores de Cannabinoides/toxicidad , Ciclohexanonas/efectos adversos , Ciclohexanonas/toxicidad , Ciclohexilaminas/efectos adversos , Ciclohexilaminas/toxicidad , Europa (Continente) , Humanos , Metanfetamina/efectos adversos , Metanfetamina/análogos & derivados , Metanfetamina/toxicidad , Piperazinas/efectos adversos , Piperazinas/toxicidad
17.
J Med Toxicol ; 8(1): 15-32, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22271566

RESUMEN

Despite their widespread Internet availability and use, many of the new drugs of abuse remain unfamiliar to health care providers. The herbal marijuana alternatives, like K2 or Spice, are a group of herbal blends that contain a mixture of plant matter in addition to chemical grade synthetic cannabinoids. The synthetic cathinones, commonly called "bath salts," have resulted in nationwide emergency department visits for severe agitation, sympathomimetic toxicity, and death. Kratom, a plant product derived from Mitragyna speciosa Korth, has opioid-like effects, and has been used for the treatment of chronic pain and amelioration of opioid-withdrawal symptoms. Salvia divinorum is a hallucinogen with unique pharmacology that has therapeutic potential but has been banned in many states due to concerns regarding its psychiatric effects. Methoxetamine has recently become available via the Internet and is marked as "legal ketamine." Moreover, the piperazine derivatives, a class of amphetamine-like compounds that includes BZP and TMFPP, are making a resurgence as "legal Ecstasy." These psychoactives are available via the Internet, frequently legal, and often perceived as safe by the public. Unfortunately, these drugs often have adverse effects, which range from minimal to life-threatening. Health care providers must be familiar with these important new classes of drugs. This paper discusses the background, pharmacology, clinical effects, detection, and management of synthetic cannabinoid, synthetic cathinone, methoxetamine, and piperazine exposures.


Asunto(s)
Alcaloides/toxicidad , Cannabinoides/toxicidad , Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Mitragyna/toxicidad , Piperazinas/toxicidad , Psicotrópicos/toxicidad , Salvia/toxicidad , Alcaloides/análisis , Alcaloides/farmacología , Alcaloides/uso terapéutico , Cannabinoides/análisis , Cannabinoides/farmacología , Cannabinoides/uso terapéutico , Ciclohexanonas/análisis , Ciclohexanonas/farmacología , Ciclohexanonas/uso terapéutico , Ciclohexilaminas/análisis , Ciclohexilaminas/farmacología , Ciclohexilaminas/uso terapéutico , Humanos , Piperazinas/análisis , Piperazinas/farmacología , Piperazinas/uso terapéutico , Psicotrópicos/análisis , Psicotrópicos/farmacología , Psicotrópicos/uso terapéutico
18.
Eur J Clin Pharmacol ; 68(5): 853-6, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22205276

RESUMEN

PURPOSE: Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a "bladder safe" derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals with acute toxicity related to the analytically confirmed use of methoxetamine. CASE SERIES: Three patients aged between 28 and 42 years presented to the Emergency Department (ED) on unrelated occasions having used methoxetamine. Clinical features were suggestive of a "dissociative/catatonic" state similar to that seen with ketamine; in addition, they had clinical features of acute sympathomimetic toxicity with significant tachycardia and hypertension. All were managed with low-dose benzodiazepines and discharged home once their symptoms/signs had settled. TOXICOLOGICAL SCREENING: Serum collected at the time of presentation to the ED was analysed qualitatively and quantitatively by gas chromatography-mass spectrometry. Serum concentrations ranged from 0.09 to 0.2 mg/L; in addition, detectable levels of 6-APB/5-APB were found in one of the patients. CONCLUSIONS: These three analytically confirmed cases demonstrate that acute methoxetamine-related toxicity is associated with both "dissociative" and "sympathomimetic" clinical features. The information from these three cases is useful to clinical pharmacologists, not only in managing individuals with acute methoxetamine toxicity but also in advising the appropriate legislative authorities on the risk of acute harm related to methoxetamine use. Further work is needed to determine whether methoxetamine is more "bladder friendly" than ketamine, as has been suggested by those marketing methoxetamine.


Asunto(s)
Ciclohexanonas/toxicidad , Ciclohexilaminas/toxicidad , Drogas Ilícitas/toxicidad , Síndromes de Neurotoxicidad/fisiopatología , Administración por Inhalación , Administración Oral , Adulto , Acatisia Inducida por Medicamentos/etiología , Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/uso terapéutico , Catatonia/etiología , Confusión/etiología , Ciclohexanonas/administración & dosificación , Ciclohexanonas/sangre , Ciclohexilaminas/administración & dosificación , Ciclohexilaminas/sangre , Tratamiento de Urgencia , Alucinaciones/etiología , Humanos , Hipertensión/etiología , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/uso terapéutico , Drogas Ilícitas/sangre , Masculino , Síndromes de Neurotoxicidad/tratamiento farmacológico , Síndromes de Neurotoxicidad/terapia , Convulsiones Febriles/etiología , Taquicardia/etiología , Resultado del Tratamiento
19.
Pharmacol Rep ; 63(1): 120-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21441619

RESUMEN

Previous studies of the propranolol monoterpene derivative (-)-4-[2-hydroxy-3-(N-isopropylamino)-propoxyimino]-cis-carane hydrochloride (KP-23) and its diastereoisomers, KP-23R and KP-23S, demonstrated different effects on the cyclic AMP generating system as well as anti-inflammatory, analgesic, antihistaminic and antioxidant activity. The present study examined the influence of KP-23 and its diastereoisomers KP-23R and KP-23S on the skin-irritating activity and the mucous membrane-irritating activity as well as their influence on a late-type contact allergy in the in vivo tests. The hydroxyl radical scavenging potential of the three analogues was evaluated using their ability to inhibit Fe(II)/H2O2-induced oxidative degradation of 2-deoxyribose (2-DR) in the in vitro tests. The results obtained indicated that the hydroxyamine carane derivative did not evoke irritative changes and did not induce a late-type contact allergy in the guinea-pig. Diastereoisomers of KP-23 exhibit antioxidant properties in a dose-dependent manner and protected against OH-radicals generated from the Fenton reaction.


Asunto(s)
Antioxidantes/farmacología , AMP Cíclico/metabolismo , Ciclohexilaminas/farmacología , Depuradores de Radicales Libres/farmacología , Animales , Antioxidantes/química , Antioxidantes/toxicidad , Monoterpenos Bicíclicos , Ciclohexilaminas/química , Ciclohexilaminas/toxicidad , Desoxirribosa/metabolismo , Dermatitis Alérgica por Contacto/etiología , Relación Dosis-Respuesta a Droga , Depuradores de Radicales Libres/química , Depuradores de Radicales Libres/toxicidad , Cobayas , Masculino , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/metabolismo , Conejos , Pruebas de Irritación de la Piel , Estereoisomerismo , Pruebas de Toxicidad/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...